Guggenheim Downgrades BioXcel Therapeutics (BTAI) to Neutral
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $1.19 +5.31%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja downgraded BioXcel Therapeutics (NASDAQ: BTAI) from Buy to Neutral.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.30 yesterday.
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
